托珠单抗治疗巨细胞动脉炎的真实世界多中心研究
该研究为观察性、开放标签、多中心研究,纳入134例因既往治疗无效或不良事件而使用托珠单抗的巨细胞动脉炎患者,评估其疗效与安全性。结果显示托珠单抗治疗后1个月93.9%患者临床改善,急性期反应物显著下降,6、12、18、24个月缓解率分别为55.5%、70.4%、69.2%和90%,严重感染发生率为10.6/100患者年,高于临床试验。
要点
- 托珠单抗治疗难治性巨细胞动脉炎1个月临床改善率达93.9%。
- 6、12、18、24个月缓解率分别为55.5%、70.4%、69.2%和90%。
- 严重感染发生率10.6/100患者年,与治疗前3个月泼尼松剂量较高相关。
核心结论
- 在临床实践中,托珠单抗对难治性巨细胞动脉炎产生快速且持续的改善。
- 严重感染发生率似乎高于临床试验。
研究设计与样本
- 观察性、开放标签、多中心研究,来自40个国家转诊中心。
- 纳入134例因既往治疗无效或不良事件而使用托珠单抗的巨细胞动脉炎患者。
- 比较了托珠单抗给药途径(皮下 vs. 静脉)、GCA病程(≤6 vs. >6个月)、有无严重感染、托珠单抗开始时泼尼松剂量≤15 vs. >15 mg/天。
主要发现
- 托珠单抗治疗1个月后93.9%患者临床改善,CRP从1.7 [0.4-3.2]降至0.11 [0.05-0.5] mg/dL(p < 0.0001),ESR从33 [14.5-61]降至6 [2-12] mm/1st小时(p < 0.0001),贫血患者比例从16.4%降至3.8%(p < 0.0001)。
- 无论给药途径或疾病病程,6、12、18、24个月达到缓解的患者比例分别为55.5%、70.4%、69.2%和90%。
- 最相关的不良事件为严重感染(10.6/100患者年),与治疗前3个月较高的泼尼松剂量相关。
临床怎么用
- 托珠单抗可用于难治性巨细胞动脉炎,快速改善临床和实验室指标。
- 治疗期间需警惕严重感染,尤其治疗前3个月泼尼松剂量较高者。
局限性
- 观察性、开放标签设计,非随机对照,可能存在选择偏倚。
- 真实世界严重感染发生率高于临床试验,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected patients with GCA in clinical practice Methods: Observational, open-label multicenter study from 40 national referral centers of GCA patients treated with TCZ due to inefficacy or adverse events of previous therapy. Outcomes variables were improvement of clinical features, acute phase reactants, glucocorticoid-sparing effect, prolonged remission and relapses. A comparative study was performed: (a) TCZ route (SC vs. IV); (b) GCA duration (≤6 vs. >6 months); (c) serious infections (with or without); (d) ≤15 vs. >15 mg/day at TCZ onset. RESULTS: 134 patients; mean age, 73.0 ± 8.8 years. TCZ was started after a median [IQR] time from GCA diagnosis of 13.5 [5.0-33.5] months. Ninety-eight (73.1%) patients had received immunosuppressive agents. After 1 month of TCZ 93.9% experienced clinical improvement. Reduction of CRP from 1.7 [0.4-3.2] to 0.11 [0.05-0.5] mg/dL (p < 0.0001), ESR from 33 [14.5-61] to 6 [2-12] mm/1st hour (p < 0.0001) and decrease in patients with anemia from 16.4% to 3.8% (p < 0.0001) were observed. Regardless of administration route or disease duration, clinical improvement leading to remission at 6, 12, 18, 24 months was observed in 55.5%, 70.4%, 69.2% and 90% of patients. Most relevant adverse side-effect was serious infections (10.6/100 patients-year), associated with higher doses of prednisone during the first three months of therapy. CONCLUSION: In clinical practice, TCZ yields a rapid and maintained improvement of refractory GCA. Serious infections appear to be higher than in clinical trials.
引用
- Calderón-Goercke M, Loricera J, Aldasoro V, et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum. 2019. PMID: 30655091. doi:10.1016/j.semarthrit.2019.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。